| 1. |
|
|
| 2. |
- Schoenmakers, Daphne H., et al.
(författare)
-
Inventory of current practices regarding hematopoietic stem cell transplantation in metachromatic leukodystrophy in Europe and neighboring countries
- 2024
-
Ingår i: Orphanet Journal of Rare Diseases. - 1750-1172. ; 19:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: For decades, early allogeneic stem cell transplantation (HSCT) has been used to slow neurological decline in metachromatic leukodystrophy (MLD). There is lack of consensus regarding who may benefit, and guidelines are lacking. Clinical practice relies on limited literature and expert opinions. The European Reference Network for Rare Neurological Diseases (ERN-RND) and the MLD initiative facilitate expert panels for treatment advice, but some countries are underrepresented. This study explores organizational and clinical HSCT practices for MLD in Europe and neighboring countries to enhance optimization and harmonization of cross-border MLD care. Methods: A web-based EUSurvey was distributed through the ERN-RND and the European Society for Blood and Marrow Transplantation Inborn Errors Working Party. Personal invitations were sent to 89 physicians (43 countries) with neurological/metabolic/hematological expertise. The results were analyzed and visualized using Microsoft Excel and IBM SPSS statistics. Results: Of the 30 countries represented by 42 respondents, 23 countries offer HSCT for MLD. The treatment is usually available in 1–3 centers per country (18/23, 78%). Most countries have no or very few MLD patients transplanted during the past 1–5 years. The eligibility criteria regarding MLD subtype, motor function, IQ, and MRI largely differ across countries. Conclusion: HSCT for MLD is available in most European countries, but uncertainties exist in Eastern and South-Eastern Europe. Applied eligibility criteria and management vary and may not align with the latest scientific insights, indicating physicians’ struggle in providing evidence-based care. Interaction between local physicians and international experts is crucial for adequate treatment decision-making and cross-border care in the rapidly changing MLD field.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Laugwitz, Lucia, et al.
(författare)
-
Newborn screening in metachromatic leukodystrophy – European consensus-based recommendations on clinical management
- 2024
-
Ingår i: European Journal of Paediatric Neurology. - 1090-3798. ; 49, s. 141-154
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Metachromatic leukodystrophy (MLD) is a rare autosomal recessive lysosomal storage disorder resulting from arylsulfatase A enzyme deficiency, leading to toxic sulfatide accumulation. As a result affected individuals exhibit progressive neurodegeneration. Treatments such as hematopoietic stem cell transplantation (HSCT) and gene therapy are effective when administered pre-symptomatically. Newborn screening (NBS) for MLD has recently been shown to be technically feasible and is indicated because of available treatment options. However, there is a lack of guidance on how to monitor and manage identified cases. This study aims to establish consensus among international experts in MLD and patient advocates on clinical management for NBS-identified MLD cases. Methods: A real-time Delphi procedure using eDELPHI software with 22 experts in MLD was performed. Questions, based on a literature review and workshops, were answered during a seven-week period. Three levels of consensus were defined: A) 100%, B) 75–99%, and C) 50–74% or >75% but >25% neutral votes. Recommendations were categorized by agreement level, from strongly recommended to suggested. Patient advocates participated in discussions and were involved in the final consensus. Results: The study presents 57 statements guiding clinical management of NBS-identified MLD patients. Key recommendations include timely communication by MLD experts with identified families, treating early-onset MLD with gene therapy and late-onset MLD with HSCT, as well as pre-treatment monitoring schemes. Specific knowledge gaps were identified, urging prioritized research for future evidence-based guidelines. Discussion: Consensus-based recommendations for NBS in MLD will enhance harmonized management and facilitate integration in national screening programs. Structured data collection and monitoring of screening programs are crucial for evidence generation and future guideline development. Involving patient representatives in the development of recommendations seems essential for NBS programs.
|
|
| 6. |
- Zanini, Luca, et al.
(författare)
-
Measurement of Volatile Radionuclides Production and Release Yields followed by a Post-Irradiation Analysis of a Pb/Bi Filled Ta Target at ISOLDE
- 2014
-
Ingår i: Nuclear Data Sheets. - : Elsevier BV. - 0090-3752. ; 119, s. 292-295
-
Tidskriftsartikel (refereegranskat)abstract
- A crucial requirement in the development of liquid-metal spallation neutron target is knowledge of the composition and amount of volatile radionuclides that are released from the target during operation. It is also important to know the total amount produced, which could be released if there was an accident. One type is the lead-bismuth eutectic (LBE) target where different radionuclides can be produced following interaction with a high-energy proton beam, notably noble gases (Ar, Kr, Xe isotopes) and other relative volatile isotopes such as Hg and At. The results of an irradiation experiment performed at ISOLDE on a LBE target are compared with predictions from the MCNPX code using the latest developments on the Liege Intranuclear Cascade model (INCL4.6) and the CEM03 model. The calculations are able to reproduce the mass distribution of the radioisotopes produced, including the At production, where there is a significant contribution from secondary reactions. Subsequently, a post-irradiation examination of the irradiated target was performed. Investigations of both the tantalum target structure, in particular the beam window, and the lead-bismuth eutectic were performed using several experimental techniques. No sign of severe irradiation damage, previously observed in other ISOLDE targets, was found.
|
|
